. Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies. Alzheimers Dement (N Y). 2022;8(1):e12296. Epub 2022 Jun 1 PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Bosutinib